Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price rose 7.8% during trading on Tuesday . The stock traded as high as $11.18 and last traded at $11.17, with a volume of 153,396 shares traded. The stock had previously closed at $10.36.

AIMT has been the subject of several research analyst reports. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, May 20th. Bank of America Corp. reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $33.40.

The firm’s market capitalization is $464.29 million. The stock has a 50 day moving average of $12.85 and a 200-day moving average of $14.49.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.03. On average, equities research analysts forecast that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of Aimmune Therapeutics stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total transaction of $3,655,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Other large investors have recently modified their holdings of the company. Alps Advisors Inc. purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $1,027,000. Aisling Capital LLC increased its stake in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares in the last quarter. Finally, TLP Group LLC purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.